\*\*



MAR 0 4 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Liming Shao

Application No:

10/014324mp

Filed:

October 26, 2001

For:

Orally-Bioavailable Formulations of

Fentanyl and Congeners Thereof

Examiner: To Be Assigned

Art Unit: To Be Assigned

Attorney Document No.: SPV-045.01

(20473-4501)

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on: February 27, 2002.

Henry Soohoo

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 (b)(3)**

Commissioner for Patents Washington, DC 20231

Sir:

In compliance with the requirements of 37 C.F.R. 1.56 and 1.97(b)(3), submitted herewith on Form PTO-1449 is a list of publications known to Applicant and his Attorney. A copy of each document is being submitted herewith. Applicant respectfully requests that the Examiner consider the listed documents and indicate they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law

regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any required fee to our **Deposit Order Account**, No. 06-1448.

Should there be any questions after reviewing this paper, the Examiner is invited to contact the undersigned at (617) 832-1000.

Date: February 27, 2002

Patent Group Foley, Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170 Respectfully Submitted,

Dana Gordon, Ph.D., JD

Reg. No. 44,719

Attorney for Applicant